Standout Papers

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose... 2010 2026 2015 2020 643
  1. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity (2010)
    Wyndham H. Wilson, Owen A. O’Connor et al. The Lancet Oncology

Immediate Impact

2 by Nobel laureates 23 from Science/Nature 62 standout
Sub-graph 1 of 21

Citing Papers

Targeting protein–ligand neosurfaces with a generalizable deep learning tool
2025 StandoutNature
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
5 intermediate papers

Works of Kieron Dunleavy being referenced

Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study
2015
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
2010 Standout
and 2 more

Author Peers

Author Last Decade Papers Cites
Kieron Dunleavy 3450 2610 1561 145 5.4k
Mats Jerkeman 3635 2511 1586 209 4.7k
Michelle A. Fanale 3946 3762 1163 249 6.2k
Jan Walewski 4453 4145 1855 207 6.8k
Hans Hagberg 3961 3064 1782 136 6.2k
Lisa M. Rimsza 3417 2577 1516 198 6.0k
Carol S. Portlock 4095 2639 1441 119 5.5k
Ann S. LaCasce 4800 3336 2230 204 7.4k
Richard Klasa 5680 3964 2344 104 7.3k
David J. Straus 4538 2840 1528 173 6.4k
Steven M. Horwitz 4562 2957 1228 234 6.7k

All Works

Loading papers...

Rankless by CCL
2026